Home /GCIG Clinical Trials By Lead Cooperative Group

GCIG Clinical Trials By Lead Cooperative Group

Disease Sitesort descending Trial Trial Number Trial Description Contact Person Trial Status Lead Cooperative Group Participating Groups
All PEACE

ClinicalTrials.gov Identifier: NCT05142150

 Studying the feasibility of collecting data on patient/carer satisfaction with end of life (EOL) care and of collecting details of that care in women with advanced gynaecological malignancies. Kristina Lindemann Recruiting NSGO-CTU ANZGOG
Cervical A18-00/ENGOT-CX11

ClinicalTrials.gov Identifier: NCT04221945

 A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Domenica Lorusso Recruiting MITO BGOG, CEEGOG, CTI, DGOG, GEICO, ISGO, MaNGO, NCRI, NOGGO
Cervical KGOG 1047/DEBULK

NCT05421650

 Therapeutic effect of surgical debulking of metastatic lymph nodes in cervical cancer stage IIICr: A phase III, randomized controlled clinical trial Recruiting KGOG KolGOTrg
Cervical GCT1015-05/ENGOT-cx8/GOG-3024

ClinicalTrials.gov Identifier: NCT03786081

 A Phase 1b/2 open-Label Trial of Tisotumab Vedotin (Humax-TF-ADC) Monotherapy and in combination with other Agents in Subjects with recurrent or Stage IVB Cervical Cancer Ignace Vergote Recruiting BGOG CEEGOG, CTI, DGOG, GOG-F, MITO, NCRI, NOGGO, NSGO-CTU, SGCTG
Cervical GOG 263

ClinicalTrials.gov Identifier: NCT01101451

 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Sang-Young Ryu Recruiting GOG
Cervical Empower Cervical 1/ ENGOT-Cx9/ GEICO 72-C/ GOG-3016

ClinicalTrials.gov Identifier: NCT03257267

 An Open Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator’s Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma Ana Oaknin Closed to Recruitment GEICO BGOG, MaNGO, MITO, NCRI
Cervical ENGOT-cx1/BGOG-cx1

ClinicalTrials.gov Identifier: NCT02009579

 Randomized double-blind Phase II study comparing carboplatin + paclitaxel with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma Ignace Vergote Closed to Recruitment BGOG GEICO, MaNGO, MITO, NOGGO
Cervical SENTICOL III

ClinicalTrials.gov Identifier: NCT03386734

 International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer Fabrice Lecuru Recruiting GINECO AGO, DGOG, GOTIC, KGOG, MaNGO, NCRI
Cervical CCTG CX.5/GCIG SHAPE

ClinicalTrials.gov Identifier: NCT01658930

 A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer; Marie Plante Closed to Recruitment CCTG AGO-AUST, BGOG, DGOG, GINECO, ICORG, KGOG, NCRI
Cervical TACO

ClinicalTrials.gov Identifier: NCT01561586

 Tri-weekly Administration of Cisplatin in Locally Advanced Cervical Cancer Sang-Young Ryu Closed to Recruitment KGOG
Cervical BEATcc/ ENGOT-Cx10/ GEICO 68-C/ JGOG1084/ GOG-3030

ClinicalTrials.gov Identifier: NCT03556839

 A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix Ana Oaknin Closed to Recruitment GEICO AGO, GINECO, GOG-F, JGOG, MaNGO, MITO, NSGO-CTU
Cervical RTOG-0724

ClinicalTrials.gov Identifier: NCT00980954

 Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy Anuja Jhingran Recruiting RTOG GOG
Cervical INTERLACE

ClinicalTrials.gov Identifier: NCT01566240

 A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer. Laura Farrelly Closed to Recruitment NCRI GICOM, KolGOTrg, MaNGO
Cervical G-GOC-1002

ClinicalTrials.gov Identifier: NCT01048853

 Conservative surgery for women with low-risk, early stage cervical cancer Kathleen Schmeler Closed to Recruitment G-GOC
Cervical ANZGOG 0902 / GOG 0274 / RTOG1174

ClinicalTrials.gov Identifier: NCT01414608

 OUTBACK TRIAL - A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone Linda Mileshkin Follow Up ANZGOG GOG, RTOG
Cervical ATOMICC/ GEICO 78-C

ClinicalTrials.gov Identifier: NCT03833479

 A randomize double-blinded, Placebo controlled, Phase II Trial of ANTI-PD1, TSR-042, as maintenance Therapy for patients with high-risk locallly advanced cervical cancer after chemo radiaton Ana Oaknin Recruiting GEICO
Cervical BRASGYN1

Universal Trial Number: UTN 1111-1238-5875

 Randomized phase III trial of Neoadjuvant Treatment in stages IB2, IIA2 and IIB of cervical cancer Mariana de Paiva Batista Recruiting BRASGYN
Cervical PMHC - CONTESSA

ClinicalTrials.gov Identifier: NCT04016389

 FIGO 2018 stage IB2 (≥2cm - <4 cm) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) / Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NeoCon-F) Valerie Bowering Recruiting PMHC DGOG
Cervical ENGOT-cx12/GOG-3037/SNGTV-003

EudraCT Number: 2019-001655-39

 A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer Ignace Vergote Recruiting BGOG GOG
Cervical 55994

ClinicalTrials.gov Identifier: NCT00039338

 Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer Stefano Greggi Closed to Recruitment EORTC-GCG
Cervical GOG 078

ClinicalTrials.gov Identifier: NCT01649089

 Studying the Physical function and Quality of Life before and after Surgery in Patients with Stage I Cervical Cancer Allan Covens Recruiting GOG
Cervical MITO CERV 2

ClinicalTrials.gov Identifier: NCT00997009

 Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer Sandro Pignata Completed MITO
Cervical G-GOC-lOOl

ClinicalTrials.gov Identifier: NCT00614211

 A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer The goal of this clinical research study is to compare the long-term outcomes of different surgical methods for the treatment of cervical cancer. The long-term outcome of a total abdominal radical hysterectomy (TARH) will be compared against laparoscopy. In this study, the laparoscopy will be done with or without robotic technology. Pedro Ramirez Closed to Recruitment G-GOC
Cervical / Endometrial GOG233 / ACRIN6671

ClinicalTrials.gov Identifier: NCT00416455

 Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Closed to Recruitment GOG ACRIN
Endometrial ENGOT-EN11/GOG-3053/KEYNOTE-B21

EudraCT: 2020-003424-17

 A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus placebo in combination with adjuvant chemotherapy with or without radiotherapy for the treatment of newly diagnosed High-Risk Endometrial Cancer after surgery with curative Intent Toon van Gorp Recruiting BGOG AGO, AGO-AUST, CEEGOG, GEICO, GINECO, GOG, GOTIC, ISGO, KGOG, MaNGO, MITO, NCRI, NSGO-CTU
Endometrial AtTEnd/ENGOT-EN7

EudraCT Number: 2018-001072-37

 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer Nicoletta Colombo Closed to Recruitment MaNGO AGO, AGO-AUST, ANZGOG, GEICO, JGOG, NCRI, SAKK
Endometrial E.C.Co. Endometrial Cancer Conservative treatment. A multicentre archive Stefano Greggi Recruiting MITO ANZGOG
Endometrial ENGOT-EN5/GOG- 3055/SIENDO

ClinicalTrials.gov Identifier: NCT03555422

 A randomized, double-blind, phase 3 trial of maintenance with selixexor/placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer. Ignace Vergote Closed to Recruitment BGOG CEEGOG, COGI-WCRN, GEICO, MITO, NOGGO
Endometrial Rainbo-MMRd-GREEN

ClinicalTrials.gov Identifier: NCT05255653  

 Rainbo: Refining adjuvant treatment IN endometrial cancer based on molecular features, transportec platform trials - MMRd - Green Judith Kroep Recruiting DGOG GINECO, NCRI
Endometrial GOG 0258

ClinicalTrials.gov Identifier: NCT00942357

 Carboplatin and Paclitaxel with or Without Cisplatin and Radiation Therapy in treating Patients with Stage I, Stage II and Sage III or Stage IVA Endometrial Cancer Closed to Recruitment GOG
Endometrial KGOG 2015

ClinicalTrials.gov Identifier: NCT01527396

 Prospective, Observational Study of Low-risk Criteria for Nod Metastasis in Endometrial Cancer Jae-Weon Kim Completed KGOG SGOG
Endometrial SAVE

ClinicalTrials.gov Identifier: NCT03422198

 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) David Gaffney Recruiting COGI-WCRN G-GOC
Endometrial KGOG 2029/SELYE

ClinicalTrials.gov Indentifier: NCT04845828

 Randomized comparison between sentinel lymph node mapping using indocyanine green plus a fluorescent camera versus lymph node dissection in clinical stage I-II endometrial cancer: a Korean Gynecologic Oncology Group trial Jeong-Yeol Park Recruiting KGOG SGOG
Endometrial AEC Cytoreductive Surgery in Advanced Endometrial Cancer. Multicenter Retrospective Study Stefano Greggi Recruiting MITO AGO-AUST, ANZGOG
Endometrial PORTEC-3

NTR Number: NTR729

ClinicalTrials.gov Identifier: NCT00411138

 Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma Carien Creutzberg Closed to Recruitment DGOG ANZGOG, CCTG, MaNGO, NCRI
Endometrial ENGOT-N2/DGCG

ClinicalTrials.gov Identifier: NCT01244789

 A Phase II Trial of Postoperative Chemotherapy or no Further Treatment for Patients With Node-negative Stage I-II Intermediate or High Risk Endometrial Cancer Mansoor Raza Mirza Closed to Recruitment NSGO-CTU BGOG, CEEGOG, EORTC-GCG, GEICO, ISGO, MaNGO, MITO, NOGGO
Endometrial AGO-OP.6/ECLAT

ClinicalTrials.gov Identifier: NCT03438474

 Endometrial Cancer Lymphadenectomy Trial (ECLAT) Philipp Harter Recruiting AGO GOTIC, KGOG
Endometrial PORTEC-4a

ClinicalTrials.gov Identifier: NCT03469674

 Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer Carien Creutzberg Closed to Recruitment DGOG CEEGOG, CTI, GINECO
Endometrial STATEC

ClinicalTrials.gov Identifier: NCT02566811

 A randomised trial of non-Selective versus selective adjuvant Therapy in high risk Apparent sTage 1 Endometrial Cancer Laura Farrelly Completed NCRI DGOG
Endometrial DOMENICA

ClinicalTrials.gov Identifier: NCT05201547

 Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting Florence Joly Recruiting GINECO AGO, ANZGOG, GEICO, KGOG, MaNGO, MITO, PMHC
Endometrial C93GOG-3064 ENGOT-EN15

ClinicalTrials.gov Identifier: NCT05173987

 Sandro Pignata Recruiting MITO BGOG, CEEGOG, CTI, DGOG, GEICO, ISGO, MaNGO, NCRI, NOGGO, NSGO-CTU
Endometrial ENGOT-EN20/GOG-3083/XPORT-EC-042

EudraCT: 2022-02540-42

 A Phase 3, Randomized, Placebo-Controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced or recurrent endometrial carcinoma Pending BGOG CEEGOG, GEICO, GOG, ISGO, MaNGO, MITO, NOGGO
Endometrial TOTEM

ClinicalTrials.gov Identifier: NCT00916708

 Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients Paolo Zola Completed MaNGO
Endometrial ENGOT-EN3/NSGO-PALEO

ClinicalTrials.gov Identifier: NCT02730429

 Trial of Letrozole +/- Palbociclib in Metastatic Endometrial Cancer Mansoor Raza Mirza Closed to Recruitment NSGO-CTU GEICO, NOGGO
Fallopian Tube & Ovarian VIP

ClinicalTrials.gov Identifier: NCT03188159

 Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer David Tan Recruiting GCGS ANZGOG
Gestational Trophoblastic Neoplasia GOG 0275

ClinicalTrials.gov Identifier: NCT01535053

 Dactinomycin or Methotrexate in Treating Patients with Low Risk Gestational Trophoblastic Neoplasia Recruiting GOG
Ovarian GLORIOSA

ClinicalTrials.gov Identifier: NCT05445778

 Randomized, multicenter, open-label, phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab Domenica Lorusso Recruiting MITO BGOG, CEEGOG, CTI, GEICO, GINECO, ISGO, MaNGO, NCRI
Ovarian ENGOT-ov54/Swiss-GO-2/MATAO

ClinicalTrials.gov Identifier: NCT04111978

 MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial Including LOGOS (Low Grade Ovarian Cancer Sub-study). Viola Heinzelmann-Schwarz Recruiting Swiss-GO AGO, AGO-AUST
Ovarian PMHC – eVolve-1 / OZM-060

ClinicalTrials.gov Identifier: NCT02340611

 A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer Valerie Bowering Closed to Recruitment PMHC
Ovarian Tarceva Trial EORTC 55041

ClinicalTrials.gov Identifier: NCT00263822

 A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. Ignace Vergote Completed EORTC-GCG
Ovarian CCTG OV.21

ClinicalTrials.gov Identifier: NCT00993655

 A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy Diane Provencher Completed CCTG GEICO, NCRI
Ovarian GOG 0281

ClinicalTrials.gov Identifier: NCT02101788

 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer David Gershenson Closed to Recruitment GOG SGCTG
Ovarian MITO23

ClinicalTrials.gov Identifier: NCT02903004

 Randomized phase III trial on Trabectedin (ET 743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients Domenica Lorusso Completed MITO MaNGO
Ovarian MITO12

ClinicalTrials.gov Identifier: NCT01061619

 Pathway to diagnosis of ovarian cancer: an observational retrospective multicentred study Sandro Pignata Completed MITO BGOG, MaNGO, NOGGO
Ovarian FIRST-ENGOT-Ov44 (ENGOT/GCIG/Tesaro)

ClinicalTrials.gov Identifier: NCT03602859

 A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer Eric Pujade-Lauraine Closed to Recruitment GINECO AGO, CEEGOG, DGOG, GEICO, MITO, NCRI, NSGO-CTU, SGCTG
Ovarian ICON 8/ICON8B

http://www.icon8trial.org/

ISRCTN10356387

ClinicalTrials.gov Identifier: NCT01654146

 An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer Laura Farrelly Closed to Recruitment NCRI ANZGOG, CTI, GICOM, KGOG, SAKK
Ovarian ENGOT-OV24/NSGO-AVANOVA1

ClinicalTrials.gov Identifier: NCT02354131

 Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Mansoor Raza Mirza Completed NSGO-CTU
Ovarian ENGOT-OV72/ROSELLA

ClinicalTrials.gov Identifier: NCT05257408

 A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Investigator’s Choice in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer Domenica Lorusso Recruiting MITO BGOG, CEEGOG, GEICO, GINECO, ISGO, NCRI
Ovarian ENGOT-OV24/NSGO-AVANOVA2

ClinicalTrials.gov Identifier: NCT02354131

 Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Mansoor Raza Mirza Completed NSGO-CTU
Ovarian ENGOT-OV62/NOGGO OV 53/N-Plus

ClinicalTrials.gov Identifier: NCT05460000

 A Phase III randomized, open label study of NiraParib maintenance after Carboplatin and Paclitaxel in optimaLly debUlked advanced HRDpositive high grade ovarian cancer patientS in first line therapy Elena Braicu Pending NOGGO AGO-AUST, BGOG, MaNGO
Ovarian AGO-OVAR 28

ClinicalTrials.gov Identifier: NCT05009082

 Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane based Chemotherapy in Advanced Ovarian Cancer Philipp Harter Recruiting AGO AGO-AUST, BGOG, CEEGOG, GEICO, MaNGO
Ovarian PMHC – NEO / OZM-058

ClinicalTrials.gov Identifier: NCT02489006

 A Phase II, Open-Label, Randomized, Multi-Centre Study of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer Valerie Bowering Closed to Recruitment PMHC
Ovarian NIRVANA-1

ClinicalTrials.gov Identifier: NCT05183984

 A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery Isabelle Ray-Coquard Recruiting GINECO BGOG, GOTIC, KGOG, MaNGO
Ovarian GOG0252

ClinicalTrials.gov Identifier: NCT00951496

 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Closed to Recruitment GOG
Ovarian SUNNY/SGOG OV4B

ClinicalTrials.gov Identifier: NCT02859038

 A Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer (SUNNY) Rongyu Zang Recruiting SGOG JGOG, KGOG
Ovarian MITO7

ClinicalTrials.gov Identifier: NCT00660842

 First line weekly carboplatin and paclitaxel versus every 3 weeks carboplatin/paclitaxel in patients with ovarian cancer: phase III multicentre trial Sandro Pignata Completed MITO GINECO, MaNGO
Ovarian CHORUS

ClinicalTrials.gov Identifier: NCT00075712

 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Jonathan Ledermann Completed NCRI
Ovarian AGO – OVAR OP.3 (LION)

ClinicalTrials.gov Identifier: NCT00712218

 Lymphadenectomy In Ovarian Neoplasms Philipp Harter Completed AGO AGO-AUST, BGOG, KGOG, MaNGO, MITO
Ovarian AGO-OVAR17

ClinicalTrials.gov Identifier: NCT01462890

 Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST) Completed AGO GINECO, NSGO-CTU
Ovarian ANITA/ ENGOT-Ov41/ GEICO 69-O

ClinicalTrials.gov Identifier: NCT03598270

A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) >6 months Antonio Gonzalez Martin Closed to Recruitment GEICO AGO, BGOG, GINECO, ISGO, MaNGO
Ovarian NSGO-CTU/HERO

ClinicalTrials.gov Identifier: NCT05574673

 Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study Mansoor Raza Mirza Recruiting NSGO-CTU
Ovarian CHRONO

ClinicalTrials.gov Identifier: NCT03579394

 Retarded surgery following neoadjuvant chemotherapy in advanced ovarian cancer Mariana de Paiva Batista Recruiting GINECO BRASGYN
Ovarian ENGOT-OV51/NItCHE/MITO33

ClinicalTrials.gov Identifier: NCT04679064

 Randomized phase III trial on NIraparib-dostarlimab vs physiscian’s choice CHEmotherapy in recurrent, platinum resistant ovarian, fallopian tube or primary peritoneal cancer Domenica Lorusso Recruiting MITO CEEGOG, GINECO, MaNGO, NOGGO
Ovarian PAOLA-1

ClinicalTrials.gov Identifier: NCT02477644

 Platine, Avastin and Olaparib in 1st line Ovarian Cancer Isabelle Ray-Coquard Completed GINECO AGO, AGO-AUST, BGOG, GOTIC, MITO
Ovarian AURELIA (GCIG/Roche)

ClinicalTrials.gov Identifier: NCT00976911

 A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer Bénédicte Votan Completed GINECO
Ovarian iPocc Trial

ClinicalTrials.gov Identifier: NCT01506856

 IntraPeritoneal therapy for Ovarian Cancer with Carboplatin (GOTIC-001 / JGOG3019) Keiichi Fujiwara Closed to Recruitment GOTIC GCGS, JGOG, KGOG
Ovarian MITO 16 MANGO OV2B

ClinicalTrials.gov Identifier: NCT01802749

 A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line Sandro Pignata Completed MITO BGOG, GINECO, MaNGO, SAKK
Ovarian ICON7

http://www.icon7trial.org/

ClinicalTrials.gov Identifier: NCT00483782 

 A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. Laura Farrelly Completed NCRI CCTG
Ovarian MITO25.1

ClinicalTrials.gov Identifier: NCT03462212

 A randomized phase II trial of Carboplatin.-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel.-Bevacizumab-Rucaparib vs Cavboplatin Paclitaxel-Rucaparib in patients with advanced (stage III-B-C-IV ) ovarian, primary peritoneal and fallopian tube cancer preceeded by a phase 1 dose escalation study onn Rucaparib Bevacizumab combination Domenica Lorusso Suspended MITO MaNGO
Ovarian AGO-OVAR12 (BI 1199.15)

ClinicalTrials.gov Identifier: NCT01015118

 Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer Philipp Harter Completed AGO AGO-AUST, BGOG, DGOG, GEICO, GINECO, MaNGO, MITO, NSGO-CTU
Ovarian AGO-OVAR OP.7/TRUST

ClinicalTrials.gov Identifier: NCT02828618

 Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST) Sven Mahner Follow Up AGO GINECO, MaNGO, NSGO-CTU
Ovarian AGO-OVAR23/DUO-O

ClinicalTrials.gov Identifier: NCT03737643

 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Philipp Harter Follow Up AGO AGO-AUST, BGOG, GEICO, GINECO, GOG-F, JGOG, KGOG, MaNGO, MITO, NSGO-CTU, PMHC
Ovarian KGOG 3046 / TRU-D

ClinicalTrials.gov Identifier: NCT03899610

 A phase II study of neoadjuvant chemotherapy plus tremelimumab and durvalumab in advanced-stage ovarian cancer Jung-Yun Lee Closed to Recruitment KGOG GCGS
Ovarian ENGOT-ov56-NSGO-CTU/DOVACC

ClinicalTrials.gov Identifier: NCT04742075

 A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent Ovarian Cancer Mansoor Raza Mirza Recruiting NSGO-CTU BGOG, CEEGOG, DGOG, NOGGO
Ovarian ENGOT-OV30/NSGO-UMBRELLA

ClinicalTrials.gov Identifier: NCT03267589

 A phase II umbrella trial in patients with relapsed ovarian cancer Mansoor Raza Mirza Completed NSGO-CTU ANZGOG, BGOG, COGI-WCRN, KGOG, NOGGO, PMHC, SGCTG
Ovarian CCTG OV.25, STICS and STONES

ClinicalTrials.gov Identifier: NCT03480776

A randomized phase II double-blind placebo-controlled trial of Acetylsalicylic acid (ASA) in chemoprevention of ovarian cancer in women with BRCA1/2 mutations Amit Oza Recruiting CCTG ANZGOG
Ovarian EWOC-1

ClinicalTrials.gov Identifier: NCT02001272

 Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer Bénédicte Votan Completed GINECO AGO, MITO
Ovarian GOG0262

ClinicalTrials.gov Identifier: NCT01167712

 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Closed to Recruitment GOG
Ovarian MOCCA

ClinicalTrials.gov Identifier: NCT03405454

 A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas David Tan Completed GCGS ANZGOG, KGOG
Ovarian IMagyn

ClinicalTrials.gov Identifier: NCT03038100

 A phase 3 multicenter randomized staudy of Atezolizumab vs placebo administered in combination with Paclitaxel,Carboplatin and Bevacizumab to patients with newly diagnosed stage III or stage IV ovarian, fallopian tube or primary peritoneal cancer Sandro Pignata Completed MITO GOG
Ovarian mEOC

ISRCTN83438782

 A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer. Completed NCRI
Ovarian AGO-OVAR16 (VEG110655)

ClinicalTrials.gov Identifier: NCT00866697 

 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy versus Placebo in Women who have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Gabriele Elser Completed AGO AGO-AUST, ANZGOG, BGOG, GEICO, GINECO, ICORG, JGOG, KGOG, MaNGO, MITO, NSGO-CTU
Ovarian & Endometrial LARA

ClinicalTrials.gov Identifier: NCT04699071

 A Multicentre Phase II trial of  Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas David Tan Recruiting GCGS KGOG
Ovarian / Rare ALIENOR-GINECO-OV222

ClinicalTrials.gov Identifier: NCT01770301

 Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours Isabelle Ray-Coquard Completed GINECO AGO, BGOG, GOTIC, MITO
Ovarian Clear Cell GCIG/JGOG3017

UMIN Registry ID: UMIN000000499

 Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary Toru Sugiyama Completed JGOG SGCTG
Ovarian newly diagnosed ENGOT-ov43/MK-7339/KEYLYNK-001

ClinicalTrials.gov Identifier: NCT03740165

 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) Ignace Vergote Closed to Recruitment BGOG CEEGOG, GEICO, GINECO, GOG, GOTIC, ISGO, KGOG, MaNGO, MITO, NOGGO, PMHC
Ovarian/Rare ROCSAN

ClinicalTrials.gov Identifier: NCT03651206

 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Isabelle Ray-Coquard Recruiting GINECO AGO, GEICO, MITO, NCRI
Recurrent Cervical GOG 240

ClinicalTrials.gov Identifier: NCT00803062

 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed GOG
Recurrent Endometrial GOG 0238

ClinicalTrials.gov Identifier: NCT00492778

 Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer Recruiting GOG
Recurrent Endometrial ENGOT-EN1/NSGO-FANDANGO

ClinicalTrials.gov Identifier: NCT02730416

 ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer Mansoor Raza Mirza Completed NSGO-CTU BGOG, GINECO, NOGGO
Recurrent Maintenance Ovarian ICON 9

ClinicalTrials.gov Identifier: NCT03278717

An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy Laura Farrelly Recruiting NCRI ANZGOG, CCTG
Recurrent Ovarian KGOG 3045 / AMBITION

ClinicalTrials.gov Identifier: NCT03699449

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer Jung-Yun Lee Closed to Recruitment KGOG GCGS
Recurrent Ovarian ATALANTE

ClinicalTrials.gov Identifier: NCT02891824

 Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab Jean-Emmanuel Kurtz Completed GINECO AGO, AGO-AUST, BGOG, CEEGOG, ISGO
Recurrent Ovarian SOLO-2 (ENGOT-GCIG/AstraZeneca)

ClinicalTrials.gov Identifier: NCT01874353

 Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy Bénédicte Votan Completed GINECO AGO, AGO-AUST, BGOG, MITO
Recurrent Ovarian AGO-OVAR 2.29

ClinicalTrials.gov Identifier: NCT03353831

 Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer Philipp Harter Follow Up AGO AGO-AUST, BGOG, GEICO, GINECO, NSGO-CTU, SAKK
Recurrent Ovarian AGO-OVAR OP.4/DESKTOP III

ClinicalTrials.gov Identifier: NCT01166737

 A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer Philipp Harter Completed AGO AGO-AUST, BGOG, GEICO, GINECO, KGOG, MaNGO, MITO, NSGO-CTU, SGOG
Recurrent Ovarian AGO-OVAR 2.21

ClinicalTrials.gov Identifier: NCT01837251

 A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer Jacobus Pfisterer Completed AGO AGO-AUST, ANZGOG, GINECO, SGCTG
Recurrent Ovarian ENGOT-ov50/GOG-3029/INNOVATE-3

ClinicalTrials.gov Identifier: NCT03940196

 Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer Ignace Vergote Closed to Recruitment BGOG AGO, CEEGOG, DGOG, GEICO, GOG, ISGO, MaNGO, MITO, NOGGO, SAKK
Recurrent Ovarian OReO-ENGOT-Ov38 (ENGOT/GCIG/AZ)

ClinicalTrials.gov Identifier: NCT03106987

 Phase III study Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Eric Pujade-Lauraine Closed to Recruitment GINECO AGO, BGOG, GEICO, ISGO, MITO, NSGO-CTU, SGCTG
Recurrent Ovarian ICON 6

http://www.icon6.org/

ISRCTN68510403

ClinicalTrials.gov Identifier: NCT00532194

 A randomised trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer. Laura Farrelly Completed NCRI ANZGOG, CCTG, GEICO
Recurrent Ovarian KGOG 3056/NIRVANA-R

ClinicalTrials.gov Identifier: NCT04734665

 A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PARP inhibitor Jung-Yun Lee Recruiting KGOG
Recurrent Ovarian INOVATYON

ClinicalTrials.gov Identifier: NCT01379989

 Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum Roldano Fossati Completed MaNGO AGO-AUST, BGOG, DGOG, GEICO, NOGGO, NSGO-CTU, SAKK
Recurrent Ovarian GOG 0213

ClinicalTrials.gov Identifier: NCT00565851

 Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Recruiting GOG
Recurrent Ovarian MITO8

ClinicalTrials.gov Identifier: NCT00657878

 Liposomal doxorubicin stealth vs. carboplatin/paclitaxel in recurrent ovarian cancer patients with platinum-free interval between 6-12 months Sandro Pignata Completed MITO AGO, BGOG, MaNGO
Recurrent Ovarian KGOG 3064/KROG 2204/SABR-ROC

NCT05444270

 Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer Yong Man Kim Recruiting KGOG
Recurrent Ovarian / Rare NiCCC

ClinicalTrials.gov Identifier: NCT02866370

 A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Ros Glasspool Closed to Recruitment SGCTG EORTC-GCG, GINECO, NSGO-CTU
Symptom Benefit ENGOT-gyn4/NOGGO S20/Expression IX

DRKS00028769

 Long-term survival with gynecological cancer Jalid Sehouli Recruiting NOGGO AGO-AUST
Symptom Benefit ENTO-OV40/NOGGO S13/Expression VI

DRKS00011339

 Caroline meets HANNA – Holistic Analysis of long-term survivors with ovarian cancer Jalid Sehouli Recruiting NOGGO AGO-AUST, BGOG, CEEGOG, GEICO
Symptom Benefit ENGOT-OV22/NOGGO S8/Expression IV Ovarian cancer patients’ expectations in respect of maintenance therapy Jalid Sehouli Completed NOGGO AGO-AUST, BGOG, GINECO, MITO, NSGO-CTU
Symptom Benefit ENGOT-EN16/NOGGO S22/Expression XI

DRKS00025954

 IMPROVE - International Survey for Endometrial Cancer patients: perspective and expectation on therapy and quality of life Jalid Sehouli Recruiting NOGGO AGO-AUST, CEEGOG, COGI-WCRN, GEICO
Symptom Benefit / Ovarian SYMPTOM BENEFIT Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Michael Friedlander Completed ANZGOG
Translational Research ENGOT-OV47/NOGGO TR2/HELP-ER Prospective Study of HE4 serum Level in Patients with First Platinum Sensitive Ovarian Cancer Relapse Jalid Sehouli Recruiting NOGGO AGO, BGOG, MITO, NCRI
Uterine Leiomyosarcoma GOG 0277

ClinicalTrials.gov Identifier: NCT01533207

 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observtion in Treating Patients with High Risk Uterine Leiomyosarcoma Previously removed by Surgery Completed GOG SGCTG
Uterine Sarcoma EORTC 62113-55115

ClinicalTrials.gov Identifier: NCT01979393

 A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment Isabelle Ray-Coquard Recruiting EORTC-GCG GOG, SGCTG
Vulvar GOG 0279

ClinicalTrials.gov Identifier: NCT01595061

 Radiation Therapy, Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Locally Advanced Squamous Cell Carcinoma of the Vulva Recruiting GOG
Vulvar GROINSS-V3

ClinicalTrials.gov Identifier: NCT05076942

 Groningen International Study on Sentinel Nodes in Vulvar Cancer-III (GROINSS-VIII) Recruiting DGOG GOG